Table 4.

Splenic marginal zone lymphoma patients treated with rituximab-based regimens.

Reference	Year	Study type	Regimen	Patient status	n	ORR (%)	Response
							Duration	OS
Rituximab monotherapy
Bennett et al.	2005	Retrospective	R monotherapy	RR	11	91%	PFS 60% at 5 years	70% at 5 years
Tsimberidou et al.	2006	Retrospective	R monotherapy	First line	25	88%	FFS 86% at 3 years	95% at 3 years
Kalpadakis et al.	2007	Retrospective	R monotherapy	First line	16	100%	PFS 92% at 2.4 years	100% at 2.1 years
Else et al.	2012	Retrospective	R monotherapy	First line and RR	10	100%	DFS 89% at 3 years	NR
Kalpadakis et al.	2013	Retrospective	R monotherapy	First line	58	95%	PFS 73% at 5 years	92% at 5 years
Rituximab + Chemotherapy
Tsimberidou et al.	2006	Retrospective	R-chemo	First line	6	83%	FFS 100% at 3 years	100% at 3 years
Else et al.	2012	Retrospective	R-chemo	First line and RR	33	100%	DFS 71% at 3 years	NR
Cervetti et al.	2013	Retrospective	R-2CDA	First line and RR	47a	87%	PFS 80% at 5 years	86% at 5 years
Iannitto et al.	2015	Prospective	R-COMP	First line	51	84%	PFS 54% at 6 years	72% at 6 years

2CDA: Cladribine; chemo: chemotherapy; DFS: disease-free survival; R: rituximab; COMP: non-pegylated lyposomal doxorubicin, cyclophosphamide, vincristine, prednisone; RR: relapsed/refractory; NR: not reported; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; FFS: failure-free survival.

^aRituximab in 32 patients.